Joshi, Yeddy, Shobha briefly detained for attempt to lay siege to DC office

Mumbai, Apr 15: A 35-year-old man, who worked as a priest in suburban Kandivali, allegedly committed suicide on Tuesday afternoon, hours after learning that lockdown to contain coronavirus has been extended.

The deceased was identified as Krishna Pujari, native of Udupi in Karnataka, who was attached to Durga Mata temple in Iraniwadi area of Sanjay Nagar.

Pujari, who lived with three other priests, was waiting for the lockdown to end as he wanted to go back to his hometown, a police official said.

When he learnt that the lockdown has been extended till May 3, he was terribly depressed and allegedly hanged himself in kitchen, the official added.

No suicide note has been found, he said.

Bengaluru, Apr 18: The Karnataka government has managed to get the contact details of nine out of 10 foreign nationals who had visited Jubilant Life Sciences, a pharmaceutical company in Mysuru district's Nanjangud which has been declared a coronavirus hotspot, State minister S Suresh Kumar said on Saturday.

As many as 66 people have tested positive for COVID-19 in Nanjangud.

While investigating the source of virus in what is now known as 'Nanjangud cluster', the Mysuru administration could get information that 10 foreign nationals had visited this town, Kumar told reporters.

Soon the External Affairs Ministry's help was sought which managed to track nine of them, Kumar said, adding that the MEA contacted its embassies in China, Germany, Japan and the USA to track these persons.

"Out of 10, they could contact nine and got details. All of them have said that they were all healthy and they did not have any symptoms.

Hence, they did not feel the need to undergo COVID-19 tests," the minister said.

He opined that many people do not show the symptoms but they could be carriers of the virus.

Coronavirus India update: State-wise total number of confirmed cases, deaths on April 18

"It all depends on the person's immunity," Kumar explained.

A foreign national from Germany who had visited Nanjangud could not be reached as her contact details were not available.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.